Background: The Wnt/β-catenin signaling pathway has been noted to be upregulated in head and neck cancers, including oropharyngeal squamous cell carcinoma (OSCC). This study compared the efficacy of β-catenin immunohistochemistry (IHC), p16 IHC and automated human papillomavirus (HPV) in situ hybridization (ISH) in OSCC. Methods: Sixty-eight OSCCs (48 surgical specimens and 20 fine-needle aspirations) were evaluated. Nuclear staining only of β-catenin was assessed as 0-3+ intensity (relative to controls of benign squamous mucosa). p16 was interpreted as positive if 70% of tumor cells showed brown nuclear and cytoplasmic staining. HPV ISH was interpreted as positive if a minimum of one tumor cell showed brown punctate dot-like nuclear positivity. p16 IHC and HPV ISH were then correlated with β-catenin staining. HPV ISH was used as the gold standard. Results: Twenty-five of 48 surgical specimens (52.1%) and 11 of 20 cell blocks (55%) stained positively for β-catenin, making a total of 36 of 68 (52.9%) staining positively for β-catenin, as compared to 61.7% positive for p16 IHC and 70.6% positive by automated HPV ISH, the gold standard method for OSCC diagnosis. χ2 analysis revealed no significant correlation between β-catenin and HPV ISH (p > 0.05) and demonstrated a strong correlation between p16 and HPV ISH (p < 0.05). Conclusion: β-Catenin IHC is not a sensitive or specific marker of HPV and is unlikely to be a useful adjunct to p16 IHC or HPV ISH in the setting of advanced OSCC. However, as this study focused on samples of advanced OSCC, β-catenin IHC may still find some use in the diagnosis of early-stage OSCC.

Keywords:
In situ hybridization, β-Catenin, p16 immunohistochemistry, Oropharyngeal carcinoma, Immunohistochemistry, Human papillomavirus
1.
Kraus C, Liehr T, Hulsken J, Behrens J, Birchmeier W, Grzeschik KH, Ballhausen WG: Localization of the human β-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development. Genomics 1994;23:272-274.
2.
Morin PJ: β-Catenin signaling and cancer. Bioessays 1999;21:1021-1030.
3.
Chang HW, Roh JL, Jeong EJ, Lee SW, Kim SW, Choi SH, Park SK, Kim SY: Wnt signaling controls radiosensitivity via cyclooxygenase-2-mediated Ku expression in head and neck cancer. Int J Cancer 2008;122:100-107.
4.
Sang HL, Bo SK, Jin MK, Songmei H, Young SR, Woo JB, Hyun JK, Young SK, Jung HM, Young CL: Wnt/β-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating Oct4. J Pathol 2014;234:99-107.
5.
Westra WH: The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol 2009;3:78-81.
6.
Bonilla-Delgado J, Bulut G, Liu X, Cortes-Malagon EM, Schlegel R, Flores-Maldonado C, Contreras RG, Chung SH, Lambert PF, Uren A, Gariglio P: The E6 oncoprotein from HPV16 enhances the canonical Wnt/β-catenin pathway in skin epidermis in vivo. Mol Cancer Res 2012;10:250-258.
7.
Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P, Psyrri A: Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res 2010;8:433-443.
8.
Hu Z, Muller S, Qian G, Xu J, Kim S, Chen Z, Jiang N, Wang D, Zhang H, Saba NF, Shin DM, Chen ZG: Human papillomavirus 16 oncoprotein regulates the translocation of β-catenin via the activation of epidermal growth factor receptor. Cancer 2015;121:214-225.
9.
Fatima N, Cohen C, Lawson D, Siddiqui MT: Automated and manual human papilloma virus in situ hybridization and p16 immunohistochemistry: comparison in metastatic oropharyngeal carcinoma. Acta Cytol 2013;57:633-640.
10.
Pukkila MJ, Virtaniemi JA, Kumpulainen EJ, Pirinen RT, Johansson RT, Valtonen HJ, Juhola MT, Kosma VM: Nuclear β catenin expression is related to unfavourable outcome in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin Pathol 2001;54:42-47.
11.
Tanaka N, Odajima T, Ogi K, Ikeda T, Satoh M: Expression of E-cadherin, α-catenin, and β-catenin in the process of lymph node metastasis in oral squamous cell carcinoma. Br J Cancer 2003;89:557-563.
12.
Santoro A, Pannone G, Papagerakis S, McGuff HS, Cafarelli B, Lepore S, De Maria S, Rubini C, Mattoni M, Staibano S, Mezza E, De Rosa G, Aquino G, Losito S, Loreto C, Crimi S, Bufo P, Lo Muzio L: β-Catenin and epithelial tumors: a study based on 374 oropharyngeal cancers. Biomed Res Int 2014;2014:948264.
13.
American Cancer Society: Oral Cavity and Oropharyngeal Cancer. New York, ACS, 2015.
14.
Bradley A, Schiff MD: Oropharyngeal squamous cell carcinoma. The Merck Manual, 2013.
15.
Simard EP, Torre LA, Jemal A: International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol 2014;50:387-403.
16.
Kaur J, Sawhney M, DattaGupta S, Shukla NK, Srivastava A, Walfish PG, Ralhan R: Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression. PLoS One 2013;8:e67361.
17.
Laxmidevi LB, Angadi PV, Pillai RK, Chandreshekar C: Aberrant β-catenin expression in the histologic differentiation of oral squamous cell carcinoma and verrucous carcinoma: an immunohistochemical study. J Oral Sci 2010;52:633-40.
18.
Balasundaram P, Manoj KS, Amit KD, Alok T, Rajni Y: Study of β-catenin, E-cadherin and vimentin in oral squamous cell carcinoma with and without lymph node metastases. Diagn Pathol 2014;9:145.
19.
Syrjanen KJ, Syrjanen SM, Lamberg MA, Pyrhonen S: Human papillomavirus (HPV) involvement in squamous cell lesions of the oral cavity. Proc Finn Dent Soc 1983;79:1-8.
20.
Muirhead DM, Hoffman HT, Robinson RA: Correlation of clinicopathological features with immunohistochemical expression of cell cycle regulatory proteins p16 and retinoblastoma: distinct association with keratinisation and differentiation in oral cavity squamous cell carcinoma. J Clin Pathol 2006;59:711-715.
21.
Ai L, Stephenson KK, Ling W, Zuo C, Mukunyadzi P, Suen JY, Hanna E, Fan CY: The p16 (CDKN2a/INK4a) tumor-suppressor gene in head and neck squamous cell carcinoma: a promoter methylation and protein expression study in 100 cases. Mod Pathol 2003;16:944-950.
22.
Buajeeb W, Poomsawat S, Punyasingh J, Sanguansin S: Expression of p16 in oral cancer and premalignant lesions. J Oral Pathol Med 2009;38:104-108.
23.
Yuen PW, Man M, Lam KY, Kwong YL: Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 2002;55:58-60.
24.
Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC: Expression of mutant nuclear β-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001;193:95-101.
25.
Tien LT, Ito M, Nakao M, Niino D, Serik M, Nakashima M, Wen CY, Yatsuhashi H, Ishibashi H: Expression of β-catenin in hepatocellular carcinoma. World J Gastroenterol 2005;11:2398-2401.
26.
Qu B, Liu BR, Du YJ, Chen J, Cheng YQ, Xu W, Wang XH: Wnt/β-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma. Oncol Lett 2014;7:1175-1178.
27.
Hugh TJ, Dillon SA, O'Dowd G, Getty B, Pignatelli M, Poston GJ, Kinsella AR: β-Catenin expression in primary and metastatic colorectal carcinoma. Int J Cancer 1999;82:504-511.
28.
Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T: Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 2001;98:10356-10361.
29.
Retera JM, Leers MP, Sulzer MA, Theunissen PH: The expression of β-catenin in non-small-cell lung cancer: a clinicopathological study. J Clin Pathol 1998;51:891-894.
30.
Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K: Expression of E-cadherin and β-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000;6:4789-4796.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.